News

Nasdaq4d
Lilly Says LY4170156 Shows Promising Safety And Anti-Tumor Activity In Phase 1 Ovarian Cancer Trial
LY4170156 is an investigational, next-generation ADC targeting Fra, a cell-surface glycoprotein encoded by the gene FOLR1 that binds to the essential nutrients folic acid and reduced folates ...
pharmaphorum2d
Lilly makes another ADC play, buying Mablink
Preclinical results with its lead candidate MBK-103, targeting the folate alpha receptor (FOLR1), were reported at the American Association of Cancer Research (AACR) meeting in March. The ...
Yahoo Finance4d
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156 ...
PipelineReview.com3d
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
INDIANAPOLIS, IN, USA I June 2, 2025 I Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) ...
Investing News Network3d
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award Contest to Support Their Professional Goals
Folate receptor alpha (FRα; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort. Sunday, June 1, 9:00 AM – 12:00 PM CDT Poster Board: 489 ...
Investing News Network3d
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 . Management will participate in a fireside chat at 10:20 a.m. Central ...